<DOC>
	<DOCNO>NCT01305200</DOCNO>
	<brief_summary>This randomized phase III trial study well Caphosol rinse work prevent mucositis young patient undergo autologous donor stem cell transplant . Supersaturated calcium phosphate ( Caphosol ) rinse may able prevent mucositis , mouth sore , patient undergo stem cell transplant .</brief_summary>
	<brief_title>Supersaturated Calcium Phosphate Rinse Preventing Oral Mucositis Young Patients Undergoing Autologous Donor Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine topically administer supersaturated calcium phosphate ( Caphosol ) , rinse orally four time daily initiation condition hematopoietic stem cell transplantation ( HSCT ) , reduce oral mucositis demonstrate decrease duration severe oral mucositis ( World Health Organization [ WHO ] grade 3 4 ) , compare placebo . SECONDARY OBJECTIVES : I . To determine whether Caphosol administration , compare placebo , reduce oral mucositis demonstrate decrease incidence severe oral mucositis ( WHO grade 3 4 ) ; severity mucositis accord mouth pain categorical rating scale Oral Mucositis Daily Questionnaire ( OMDQ ) ; incidence , total dose , duration parenteral opioid analgesic use ( morphine equivalent ) ; incidence duration total parenteral nutrition ( TPN ) administration . II . To determine whether Caphosol administration , compare placebo , reduce incidence febrile neutropenia invasive bacterial infection . III . To validate new pediatric measure oral mucositis term Children 's International Mucositis Evaluation Scale ( ChIMES ) . OUTLINE : This multicenter study . Patients stratify accord condition regimen ( total-body irradiation ( TBI ) melphalan v neither TBI melphalan ) hematopoietic stem cell transplantation ( HSCT ) ( autologous v allogeneic ) . Patients randomize 1 2 treatment arm . ARM I : Patients rinse gargle supersaturated calcium phosphate rinse 1 minute four* time daily ( QID ) begin first day ( day -7 ) condition regimen . ARM II : Patients rinse gargle placebo 1 minute QID* begin first day ( day -7 ) condition regimen . NOTE : * Patients reach WHO grade 3 4 mucositis option request total 6 rinse daily . In arm , treatment continue day 20 post-transplantation OR mucositis resolve WHO grade = &lt; 2 two consecutive day OR day 12 patient experience oral mucositis least WHO grade &gt; = 1 . Patients assessed daily train healthcare professional use Oral Mucositis Daily Questionnaire ( OMDQ ) , Pain Rating Scale , WHO Mucositis Scale , Children 's International Mucositis Evaluation Scale ( ChIMES ) day -1 continue day 20 . Patients also observe incidence total dose duration parenteral opioid analgesic use , duration total parenteral nutrition ( TPN ) administration , febrile neutropenia , invasive bacterial infection . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Embryonal</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Leukemia , Neutrophilic , Chronic</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<criteria>Patients undergo myeloablative autologous allogeneic hematopoietic stem cell transplantation ( HSCT ) indication One follow donor stem cell source ( autologous allogeneic ) : Bone marrow Placental blood ( umbilical cord blood ) Cytokinemobilized peripheral blood Patients eligible allogeneic HSCT must one follow type donor stem cell : Human leukocyte antigen ( HLA ) match sibling parent Partially match family donor ( mismatch single HLA locus [ Class I ] ) Fully match unrelated marrow peripheral blood stem cell donor HLAmatched partially mismatch ( least 4 6 match ) cord blood ( Class I II ) Patients expect receive type myeloablative HSCT condition regimen eligible No nonmyeloablative reducedintensity conditioning regimen Eligible patient must receive palifermin within 30 day prior enrollment Eligible patient must receive prior treatment Caphosol Females childbearing potential must negative pregnancy test ; patient must agree use effective birth control method ; lactate patient must agree nurse child trial</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>